Abstract
C4 Therapeutics has launched from James E. Bradner’s lab at Dana-Farber Cancer Institute with $73 million in financing. The firm is developing Degronimids, small-molecule binders that target disease-causing proteins and facilitate their clearance from cells through the natural ubiquitin-proteasome system. The molecules offer a promising approach for previously undruggable proteins, it says. At the same time, C4 will work with Roche to develop Degronimids against unspecified targets. The deal could be worth more than $750 million.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
